Curis Inc (CRIS) - Net Assets
Based on the latest financial reports, Curis Inc (CRIS) has net assets worth $12.71 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.69 Million) and total liabilities ($16.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Curis Inc (CRIS) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.71 Million |
| % of Total Assets | 42.8% |
| Annual Growth Rate | -5.45% |
| 5-Year Change | -93.98% |
| 10-Year Change | -81.34% |
| Growth Volatility | 141.99 |
Curis Inc - Net Assets Trend (1999–2025)
This chart illustrates how Curis Inc's net assets have evolved over time, based on quarterly financial data. See Curis Inc (CRIS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Curis Inc (1999–2025)
The table below shows the annual net assets of Curis Inc from 1999 to 2025. For live valuation and market cap data, see Curis Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.46 Million | +191.06% |
| 2024-12-31 | $-6.00 Million | -130.49% |
| 2023-12-31 | $19.67 Million | -57.75% |
| 2022-12-31 | $46.55 Million | -48.68% |
| 2021-12-31 | $90.71 Million | -30.58% |
| 2020-12-31 | $130.67 Million | +485.33% |
| 2019-12-31 | $-33.91 Million | -654.25% |
| 2018-12-31 | $-4.50 Million | -118.74% |
| 2017-12-31 | $23.99 Million | -18.02% |
| 2016-12-31 | $29.27 Million | -54.63% |
| 2015-12-31 | $64.51 Million | +116.60% |
| 2014-12-31 | $29.78 Million | -34.07% |
| 2013-12-31 | $45.17 Million | +31.83% |
| 2012-12-31 | $34.27 Million | -14.06% |
| 2011-12-31 | $39.88 Million | -12.39% |
| 2010-12-31 | $45.52 Million | +37.71% |
| 2009-12-31 | $33.05 Million | -11.21% |
| 2008-12-31 | $37.22 Million | -20.54% |
| 2007-12-31 | $46.84 Million | +30.50% |
| 2006-12-31 | $35.90 Million | -5.53% |
| 2005-12-31 | $38.00 Million | -22.31% |
| 2004-12-31 | $48.91 Million | +25.84% |
| 2003-12-31 | $38.87 Million | +109.60% |
| 2002-12-31 | $18.54 Million | -81.64% |
| 2001-12-31 | $101.02 Million | -40.16% |
| 2000-12-31 | $168.81 Million | +620.76% |
| 1999-12-31 | $23.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Curis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 112578597600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $129.00K | 2.36% |
| Other Components | $1.25 Billion | 22935.08% |
| Total Equity | $5.46 Million | 100.00% |
Curis Inc Competitors by Market Cap
The table below lists competitors of Curis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MOGU Inc
NYSE:MOGU
|
$15.83 Million |
|
Orbital Corporation Ltd
AU:OEC
|
$15.84 Million |
|
Robot S.A.
MC:RBT
|
$15.84 Million |
|
PRI EKOPARK SA ZY -10
F:NPA
|
$15.85 Million |
|
Linkage Global Inc
NASDAQ:UZX
|
$15.83 Million |
|
Hanchang
KO:005110
|
$15.81 Million |
|
Intelligent Protection Management Corp
NASDAQ:IPM
|
$15.81 Million |
|
Bertam Alliance Bhd
KLSE:9814
|
$15.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Curis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -5,998,000 to 5,462,000, a change of 11,460,000.
- Net loss of 7,582,000 reduced equity.
- New share issuances of 15,352,000 increased equity.
- Other factors increased equity by 3,690,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.58 Million | -138.81% |
| Share Issuances | $15.35 Million | +281.07% |
| Other Changes | $3.69 Million | +67.56% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Curis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 9.79x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $219.27 | $0.41 | x |
| 2000-12-31 | $954.08 | $0.41 | x |
| 2001-12-31 | $317.08 | $0.41 | x |
| 2002-12-31 | $57.47 | $0.41 | x |
| 2003-12-31 | $107.91 | $0.41 | x |
| 2004-12-31 | $114.58 | $0.41 | x |
| 2005-12-31 | $79.04 | $0.41 | x |
| 2006-12-31 | $73.16 | $0.41 | x |
| 2007-12-31 | $85.30 | $0.41 | x |
| 2008-12-31 | $58.73 | $0.41 | x |
| 2009-12-31 | $50.80 | $0.41 | x |
| 2010-12-31 | $60.72 | $0.41 | x |
| 2011-12-31 | $52.23 | $0.41 | x |
| 2012-12-31 | $43.34 | $0.41 | x |
| 2013-12-31 | $54.86 | $0.41 | x |
| 2014-12-31 | $34.64 | $0.41 | x |
| 2015-12-31 | $52.29 | $0.41 | x |
| 2016-12-31 | $22.04 | $0.41 | x |
| 2017-12-31 | $16.09 | $0.41 | x |
| 2018-12-31 | $-2.72 | $0.41 | x |
| 2019-12-31 | $-20.44 | $0.41 | x |
| 2020-12-31 | $53.70 | $0.41 | x |
| 2021-12-31 | $19.81 | $0.41 | x |
| 2022-12-31 | $9.97 | $0.41 | x |
| 2023-12-31 | $3.72 | $0.41 | x |
| 2024-12-31 | $-0.95 | $0.41 | x |
| 2025-12-31 | $0.04 | $0.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Curis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -138.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -80.29%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 3.66x
- Recent ROE (-138.81%) is below the historical average (-83.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -51.70% | -377.03% | 0.11x | 1.23x | $-14.45 Million |
| 2000 | -207.54% | -35137.73% | 0.01x | 1.08x | $-367.23 Million |
| 2001 | -81.04% | -7534.60% | 0.01x | 1.43x | $-91.97 Million |
| 2002 | -443.93% | -447.60% | 0.29x | 3.37x | $-84.17 Million |
| 2003 | -29.91% | -105.20% | 0.20x | 1.43x | $-15.51 Million |
| 2004 | -28.43% | -280.75% | 0.07x | 1.38x | $-18.80 Million |
| 2005 | -39.09% | -247.49% | 0.10x | 1.60x | $-18.66 Million |
| 2006 | -24.60% | -59.12% | 0.29x | 1.46x | $-12.42 Million |
| 2007 | -14.87% | -42.49% | 0.30x | 1.15x | $-11.65 Million |
| 2008 | -32.57% | -144.90% | 0.21x | 1.07x | $-15.85 Million |
| 2009 | -29.72% | -114.35% | 0.24x | 1.09x | $-13.13 Million |
| 2010 | -9.74% | -27.72% | 0.32x | 1.11x | $-8.99 Million |
| 2011 | -24.72% | -66.78% | 0.31x | 1.21x | $-13.85 Million |
| 2012 | -47.91% | -96.73% | 0.24x | 2.04x | $-19.84 Million |
| 2013 | -27.28% | -82.14% | 0.19x | 1.78x | $-16.84 Million |
| 2014 | -62.88% | -190.27% | 0.16x | 2.10x | $-21.71 Million |
| 2015 | -91.43% | -748.64% | 0.08x | 1.47x | $-65.43 Million |
| 2016 | -206.42% | -802.59% | 0.13x | 1.97x | $-63.34 Million |
| 2017 | -222.22% | -538.66% | 0.13x | 3.08x | $-55.72 Million |
| 2018 | 0.00% | -312.38% | 0.28x | 0.00x | $-32.13 Million |
| 2019 | 0.00% | -321.28% | 0.28x | 0.00x | $-28.75 Million |
| 2020 | -22.89% | -276.03% | 0.05x | 1.56x | $-42.98 Million |
| 2021 | -50.09% | -426.67% | 0.07x | 1.79x | $-54.51 Million |
| 2022 | -129.58% | -593.62% | 0.09x | 2.34x | $-64.98 Million |
| 2023 | -241.04% | -473.04% | 0.13x | 3.93x | $-49.38 Million |
| 2024 | 0.00% | -397.77% | 0.26x | 0.00x | $-42.79 Million |
| 2025 | -138.81% | -80.29% | 0.47x | 3.66x | $-8.13 Million |
Industry Comparison
This section compares Curis Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Curis Inc (CRIS) | $12.71 Million | -51.70% | 1.34x | $15.83 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. … Read more